Court Report

By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cadence Pharmaceuticals Inc. et al. v. InnoPharma Licensing LLC et al. 1:14-cv-01225; filed September 24, 2014 in the District Court of Delaware • Plaintiffs: Cadence Pharmaceuticals Inc.; SCR Pharmatop; Mallinckrodt IP • Defendants: InnoPharma Licensing LLC; InnoPharma Inc. Infringement of U.S. Patent Nos. 6,028,222 (“Stable Liquid Paracetamol Compositions, and Method for Preparing the Same,” issued February 22, 2000) and 6,992,218 (“Method for Obtaining Aqueous Formulations of Oxidation-Sensitive Active Principles,” issued January 31, 2006), both licensed to Cadence, following a Paragraph…
Read the full story here: Patent Docs

Conference & CLE Calendar

September 23, 2014 – First Inventor to File America Invents Act Roadshow (U.S. Patent and Trademark Office) – Alexandria, VA (webcast) September 24, 2014 – “Trade Secrets in the Life Sciences” (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET) September 25, 2014 – “Charting New Territory: Prosecution and Diligence Strategies in the Wake of the AIA” (American Bar Association Center for Professional Development and Section of Intellectual Property Law) – 1:00 to 2:30 pm (ET) September 26, 2014 – IP & Diagnostics Symposium (Biotechnology Industry Organization) – Alexandria, VA September 30, 2014 – 2014 Intellectual Property Continuing Legal…
Read the full story here: Patent Docs

Eligible Software Patents

I’m looking for a few examples of high quality software patents outside of the business method realm and that should remain patent eligible under Alice & Bilski. Only send me ideas that you are fine with being publicly discussed. DC
Read the full story here: Patently-O » Patent

Inovia Releases 2014 Report on Global Patent Trends

By Donald Zuhn — Patent services provider inovia has released its fifth annual report on global patent and IP trends. In compiling “The 2014 U.S. Global Patent & IP Trends Indicator,” inovia, which produces products for PCT national phase entry, European patent validation, and patent translations, surveyed more than 100 companies and universities in May 2014 to identify the trends having the greatest impact on the foreign filing strategies of U.S. patentees. The 2014 report notes that 20.4% of survey respondents are involved in the pharmaceuticals or biotech industries. Other sectors or groups represented in the survey include chemicals/materials (13.6%),…
Read the full story here: Patent Docs

In re Lipitor Antitrust Litigation (D.N.J. 2014)

By Kevin E. Noonan — In the lastest instance of a plaintiff attempting to extend the Supreme Court’s holding in FTC v. Actavis that “reverse payment” settlement agreements in ANDA litigation could be anticompetitive and violate the antitrust laws, the District Court of New Jersey (P. Sheridan, J.) granted defendants’ motion to dismiss under Fed. R. Civ. Pro. 12(b)(6) for failure to state a claim (Memorandum). While acknowledging that the Court’s Actavis decision could apply to agreements where consideration other than money was exchanged between a branded drug company and its generic drug challenger, the District Court held that the…
Read the full story here: Patent Docs

Get Adobe Flash playerPlugin by wordpress themes